Yazar "Colak, A." seçeneğine göre listele
Listeleniyor 1 - 3 / 3
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Correlation between Bethatrophin and 25(OH)D Concentrations in a Group of Subjects With Normal and Impaired Glucose Metabolism(Georg Thieme Verlag Kg, 2017) Turkon, H.; Yalcin, H.; Toprak, B.; Demirpence, M.; Yasar, H. Y.; Colak, A.Aim Inducing beta cell replication is a potential therapeutic approach for the treatment of diabetes mellitus. Recently betatrophin was suggested as a novel stimulator of beta cell proliferation in mice but its role in humans remains to be established. We aimed to investigate betatrophin concentration and its association with metabolic parameters in a group of individuals with normal glucose tolerance, pre-diabetes and diabetes mellitus who had not been previously treated. Methods A total of 72 subjects were recruited for this cross sectional study: 23 subjects with normal glucose tolerance (NGT), 22 subjects with prediabetes, and 27 subjects with diabetes mellitus (DM). Circulating betatrophin concentration, 75 g oral glucose tolerance test, fasting insulin, glycosylated hemoglobin, 25hydroxy vitamin D and HOMA IR were measured. Results The difference in betatrophin values did not reach statistical significance between the 3 groups [NGT: 206 (176-297) pg/mL, Prediabetes: 232 (181-254) pg/mL, DM: 245 (205-526) pg/mL, p = 0.078]. Betatrophin was negatively significantly correlated with BMI and positively significantly correlated with 25(OH) vitD (p = 0.043 and p = 0.001 respectively). Multivariate linear regression showed that 25(OH) vitD (beta = 0.440 p = 0.001) and fasting glucose (beta = 0.003 p = 0.038) were variables associated with betatrophin concentration (R2 = 0.251). Conclusions In a group of subjects ranging from those with normal glucose tolerance to newly diagnosed diabetes, we found that 25(OH) D and fasting glucose were factors associated with serum betatrophin concentration.Öğe Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly?(Springer, 2019) Demirpence, M.; Guler, A.; Yilmaz, H.; Sayin, A.; Pekcevik, Y.; Turkon, H.; Colak, A.PurposeAcromegaly is a rare disorder existed in the result of overproduction of growth hormone (GH). The disorder is associated with increased cardiovascular risk factors and metabolic abnormalities. Urotensin II (UII), a secreted vasoactive peptide hormone, belonging somatostatin superfamily, plays an essential role in atherosclerosis and glucose metabolism. The aim of this study was to ascertain whether circulating UII levels are altered in subjects with acromegaly, and to describe the relationship between UII and hormonal or cardiometabolic parameters. MethodsThis cross-sectional study included 41 subjects with active acromegaly, 28 subjects with controlled acromegaly, and 37 age- and BMI-matched controls without acromegaly. Hormonal and metabolic features of the subjects as well as carotid intima media thickness (cIMT) and epicardial fat thickness (EFT) were defined. Circulation of UII levels was determined via ELISA.ResultsBoth active and controlled acromegalic subjects showed a significant elevation of circulating levels of UII with respect to controls. There was no remarkable difference in circulating levels of UII between active and controlled acromegalic groups. Both cIMT and EFT were remarkably increased in acromegaly subjects comparing to controls. UII positively correlated with cIMT, EFT, BMI, and HOMA-IR. There was no correlation between UII and GH, insulin-like growth factor-1. According to the results obtained from regression models, UII levels independently predicted cIMT and EFT.ConclusionElevated UII levels are associated with severity of cardiovascular risk factors including cIMT and EFT in acromegalic subjects.Öğe Serum irisin levels in patients with morbid obesity(Wiley-Blackwell, 2016) Colak, A.; Yalcin, H.; Toprak, B.; Turkon, H.; Demirpence, M.; Yilmaz, H.; Bozkurt, U.[Anstract Not Available]
